Potential Vaccines for Treating Crohn's Disease

Rostami-Nejad, Mohammad; Yazdi, Mohammad Hossein; Nikfar, Shekoufeh; Rezaie, Ali; Abdollahi, Mohammad

doi:10.29252/ibj.24.1.1

Cited by 2 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro studies have shown that serum IL-23 p19-specific IgG significantly suppresses IL-23-induced IL-17 production by splenocytes. In vivo evaluations of the vaccine’s effect on mice with chronic colitis indicated that vaccine-immunized mice exhibited a decrease in colon inflammation, collagen deposition, and levels of IL-23 and IL-12 cytokines compared with the control groups [ 178 , 179 ]. It appears possible to develop a vaccine that would help control immune responses in this inflammatory disease.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease

Korta,

Kula,

Gomułka

2023

IJMS

View full text Add to dashboard Cite

Interleukin-23 (IL-23) is a proinflammatory cytokine produced mainly by macrophages and antigen-presenting cells (APCs) after antigenic stimulation. IL-23 plays a significant role as a mediator of tissue damage. Indeed, the irregularities in IL-23 and its receptor signaling have been implicated in inflammatory bowel disease. IL-23 interacts with both the innate and adaptive immune systems, and IL-23/Th17 appears to be involved in the development of chronic intestinal inflammation. The IL-23/Th17 axis may be a critical driver of this chronic inflammation. This review summarizes the main aspects of IL-23’s biological function, cytokines that control cytokine production, effectors of the IL-23 response, and the molecular mechanisms associated with IBD pathogenesis. Although IL-23 modulates and impacts the development, course, and recurrence of the inflammatory response, the etiology and pathophysiology of IBD are not completely understood, but mechanism research shows huge potential for clinical applications as therapeutic targets in IBD treatment.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease

Korta,

Kula,

Gomułka

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Last but not least, in phase III, the effectiveness of the vaccine is verified to determine its effectiveness in preventing infection with the targeted virus [ 11 ]. A major difference though, is the preventive application of a vaccine [ 12 ]. This means that typically a large population of healthy people, often a group of high risk patients of the infection to be studied, are vaccinated to quantify the effect of vaccination on the probability of contracting the infection and the severity of its course [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccines: ethical framework concerning human challenge studies

et al. 2020

View full text Add to dashboard Cite

Background The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. Objectives To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, Results Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. Conclusions One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. Graphical abstract

show abstract

Potential Vaccines for Treating Crohn's Disease

Cited by 2 publications

References 77 publications

The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease

The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease

COVID-19 vaccines: ethical framework concerning human challenge studies

Contact Info

Product

Resources

About